NBIX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +1.82
Percentage change 1.33	%

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: IJH VTI VB VXF VBK XBI MDY IBB IJK USMV

Scroll to Statements

Index	-	P/E	37.06	EPS (ttm)	3.73	Insider Own	2.68%	Shs Outstand	101.20M	Perf Week	2.14%
Market Cap	14.01B	Forward P/E	21.88	EPS next Y	6.32	Insider Trans	-3.31%	Shs Float	98.54M	Perf Month	8.84%
Income	385.90M	PEG	0.63	EPS next Q	1.57	Inst Own	91.86%	Short Float	3.44%	Perf Quarter	19.33%
Sales	2.24B	P/S	6.25	EPS this Y	68.21%	Inst Trans	-0.49%	Short Ratio	3.55	Perf Half Y	3.00%
Book/sh	26.87	P/B	5.15	EPS next Y	52.17%	ROA	12.09%	Short Interest	3.39M	Perf Year	5.45%
Cash/sh	12.13	P/C	11.41	EPS next 5Y	59.00%	ROE	16.35%	52W Range	110.95 - 157.98	Perf YTD	5.00%
Dividend Est.	-	P/FCF	31.83	EPS past 5Y	62.04%	ROI	12.99%	52W High	-12.43%	Beta	0.34
Dividend TTM	-	Quick Ratio	4.26	Sales past 5Y	34.77%	Gross Margin	97.53%	52W Low	24.69%	ATR (14)	3.30
Dividend Ex-Date	Dec 29, 1995	Current Ratio	4.37	EPS Y/Y TTM	96.91%	Oper. Margin	26.23%	RSI (14)	70.91	Volatility	2.73% 2.33%
Employees	1400	Debt/Eq	0.11	Sales Y/Y TTM	25.72%	Profit Margin	17.21%	Recom	1.41	Target Price	166.62
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	51.40%	Payout	0.00%	Rel Volume	0.64	Prev Close	136.53
Sales Surprise	3.57%	EPS Surprise	-17.62%	Sales Q/Q	24.72%	Earnings	Oct 30 BMO	Avg Volume	953.72K	Price	138.35
SMA20	5.84%	SMA50	10.66%	SMA200	4.02%	Trades		Volume	519,586	Change	1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130
Oct-11-22	Initiated	UBS	Buy	$136
Sep-26-22	Initiated	Wells Fargo	Equal Weight	$110
Jun-06-22	Resumed	Jefferies	Buy	$126 → $112
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral	$114 → $94
Feb-25-22	Upgrade	Goldman	Neutral → Buy	$115
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$122 → $90

Show Previous Ratings

Dec-24-24 03:23PM	Neurocrine Biosciences Stock Sees RS Rating Upgrade (Investor's Business Daily)
Dec-20-24 08:00AM	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia (PR Newswire)
Dec-16-24 04:10PM	Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug (Investor's Business Daily) +5.01%
09:10AM	Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential (Benzinga)
Dec-13-24 07:00PM	Neurocrine Wins FDA Approval For Genetic Disorder Drug (Investor's Business Daily)
06:55PM	Loading…
06:55PM	Neurocrine Biosciences Announces FDA Approval of CRENESSITY (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia (PR Newswire)
Dec-02-24 01:55PM	Why Is Neurocrine Biosciences, Inc. (NBIX) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-30-24 04:31PM	Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now? (Insider Monkey)
Nov-26-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in December (PR Newswire)
Nov-07-24 08:30AM	Neurocrine Biosciences Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-05-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in November (PR Newswire)
Nov-04-24 08:30AM	Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA (valbenazine) Capsules (PR Newswire)
08:25AM	Neurocrine Biosciences Presents New Data on INGREZZA (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia (PR Newswire)
Oct-31-24 03:04AM	Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ... (GuruFocus.com)
01:09AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
09:30AM	Loading…
Oct-30-24 09:30AM	Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +7.01%
08:10AM	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates (Zacks)
07:07AM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance (PR Newswire)
Oct-23-24 10:56AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
10:01AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-17-24 01:02PM	State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc (GuruFocus.com)
Oct-16-24 04:04PM	Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-09-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results (PR Newswire)
Sep-30-24 08:30AM	Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use (PR Newswire)
Sep-19-24 04:01PM	Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit (PR Newswire)
Sep-14-24 07:25PM	Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock (Insider Monkey)
Sep-13-24 04:32AM	Neurocrines Phase II schizophrenia trial fails to meet primary endpoint (Clinical Trials Arena)
Sep-12-24 04:05PM	Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia (PR Newswire)
Sep-10-24 04:01PM	Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (PR Newswire)
10:53AM	Loading…
Sep-02-24 10:53AM	Nxera wins $35m after Phase II schizophrenia trial success (Pharmaceutical Technology)
Aug-30-24 07:41AM	Why Neurocrine Biosciences Stock Was Tumbling This Week (Motley Fool)
Aug-29-24 01:22PM	Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock (Benzinga)
06:52AM	Neurocrine reports positive data from Phase II schizophrenia treatment trial (Clinical Trials Arena)
Aug-28-24 06:19PM	Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday (Investopedia) -18.87%
04:28PM	Neurocrine Plummets 19% Does It Still Have A Shot At This 'Significant Market Opportunity?' (Investor's Business Daily)
04:05PM	Neurocrine Biosciences to Participate at Investor Conferences in September (PR Newswire)
11:16AM	As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors (Benzinga)
09:56AM	Neurocrine Stock Hammered After Schizophrenia Drug Lags Two Key Rivals (Investor's Business Daily)
08:17AM	Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers (Investor's Business Daily)
08:15AM	Neurocrines mixed schizophrenia data disappoint Wall Street (BioPharma Dive)
07:07AM	Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 (GlobeNewswire)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia (PR Newswire)
Aug-16-24 07:01PM	Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Aug-07-24 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Aug-06-24 12:45PM	Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Aug-02-24 06:39AM	Vir retreats from infectious disease; Vertex shelves AATD drugs (BioPharma Dive)
01:05AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 10:00AM	Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics (Zacks) +8.18%
08:06AM	Neurocrine Biosciences Raises 2024 INGREZZA Net Product Sales Guidance (RTT News)
08:05AM	Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates (Zacks)
07:09AM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance (PR Newswire)
Jul-31-24 09:15AM	Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics (Zacks)
Jul-25-24 10:02AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-18-24 08:30AM	Neurocrine Biosciences Launches INGREZZA SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing (PR Newswire)
Jul-12-24 08:38AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
Jul-11-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results (PR Newswire)
Jul-02-24 06:33AM	FDA grants priority review for Neurocrines crinecerfont NDAs (Pharmaceutical Technology)
Jul-01-24 07:30AM	Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH (PR Newswire)
Jun-28-24 04:37PM	How Medicare drug price negotiations could hit pharma stocks (Yahoo Finance Video)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-14-24 02:34PM	Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans (Investor's Business Daily)
Jun-03-24 08:01AM	Neurocrine Biosciences Presented CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 (PR Newswire)
07:35AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
07:30AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
May-29-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in June (PR Newswire)
May-28-24 04:14PM	Neurocrine Biosciences Announces CEO Succession Plan (PR Newswire)
08:30AM	Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 (PR Newswire)
May-21-24 04:05PM	Neurocrine Biosciences Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA (valbenazine) Capsules (PR Newswire)
May-16-24 04:47PM	Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing (MT Newswires)
May-14-24 08:30AM	Neurocrine Biosciences Presented Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 (PR Newswire)
May-09-24 11:51AM	How Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 And Outperforming Peers (Investor's Business Daily)
11:51AM	How Neurocrine Is Stacking Up Wins In 2024 And Outperforming Peers (Investor's Business Daily)
09:45AM	Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 (PR Newswire)
08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults (PR Newswire)
02:35AM	Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults (GlobeNewswire)
May-08-24 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults (PR Newswire)
May-07-24 04:15PM	Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference (PR Newswire)
08:30AM	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 (PR Newswire)
May-06-24 08:30AM	Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring (PR Newswire)
May-04-24 08:00AM	Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam (Investor's Business Daily)
May-03-24 01:15PM	Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 (PR Newswire)
May-02-24 11:18AM	UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating (MT Newswires)
03:01AM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
01:06AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
May-01-24 11:36PM	Q1 2024 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
09:01PM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
04:18PM	Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech (Investor's Business Daily)
11:54AM	NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:04AM	No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win (Investor's Business Daily)
08:31AM	Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell (MT Newswires)
08:15AM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
07:18AM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 05:48PM	REFILE-UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval (April 30) (Reuters)
05:45PM	Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours (MT Newswires)
05:31PM	FDA approves Neurocrine Biosciences' Huntington's disease drug (Reuters)
05:12PM	Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules (PR Newswire)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Delaet Ingrid	Chief Regulatory Officer	Dec 17 '24	Option Exercise	79.02	1,091	86,211	3,598	Dec 19 04:37 PM
Delaet Ingrid	Chief Regulatory Officer	Dec 17 '24	Sale	135.00	1,091	147,285	2,507	Dec 19 04:37 PM
INGRID DELAET	Officer	Dec 17 '24	Proposed Sale	133.05	1,091	145,158		Dec 17 04:29 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '24	Option Exercise	0.00	4,426	0	17,780	Dec 03 06:52 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '24	Sale	126.29	2,331	294,373	15,449	Dec 03 06:52 PM
JUDE ONYIA	Officer	Nov 29 '24	Proposed Sale	126.59	2,331	295,081		Nov 29 01:41 PM
ROBERTS EIRY	Chief Medical Officer	Nov 08 '24	Option Exercise	81.67	7,345	599,873	31,061	Nov 12 05:58 PM
Boyer David W.	Chief Corp. Affairs Officer	Sep 13 '24	Sale	121.88	3,461	421,828	1,672	Sep 17 04:21 PM
DAVID WARREN BOYER	Officer	Sep 13 '24	Proposed Sale	121.28	4,756	576,808		Sep 13 04:23 PM
RASTETTER WILLIAM H	Director	Aug 15 '24	Sale	146.69	14,250	2,090,332	37,491	Aug 16 05:00 PM
LYONS GARY A	Director	Aug 13 '24	Option Exercise	42.76	11,570	494,733	130,617	Aug 15 05:21 PM
LYONS GARY A	Director	Aug 13 '24	Sale	150.43	11,570	1,740,450	119,047	Aug 15 05:21 PM
ABERNETHY MATT	Chief Financial Officer	Aug 13 '24	Option Exercise	73.60	14,100	1,037,760	45,628	Aug 15 05:12 PM
ABERNETHY MATT	Chief Financial Officer	Aug 13 '24	Sale	150.38	14,100	2,120,347	31,528	Aug 15 05:12 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 13 '24	Option Exercise	103.52	3,043	315,011	9,650	Aug 15 05:06 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 13 '24	Sale	150.10	7,143	1,072,180	2,507	Aug 15 05:06 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 06 '24	Option Exercise	79.02	273	21,572	6,880	Aug 08 05:16 PM
Delaet Ingrid	Chief Regulatory Officer	Aug 06 '24	Sale	147.70	273	40,322	6,607	Aug 08 05:16 PM
Cooke Julie	Chief Human Resources Officer	Aug 01 '24	Option Exercise	61.82	12,632	780,910	30,834	Aug 05 05:40 PM
Cooke Julie	Chief Human Resources Officer	Aug 01 '24	Sale	153.26	12,632	1,936,017	18,202	Aug 05 05:40 PM
Lippoldt Darin	Chief Legal Officer	Aug 01 '24	Option Exercise	79.02	2,996	236,744	42,736	Aug 05 05:18 PM
Lippoldt Darin	Chief Legal Officer	Aug 01 '24	Sale	154.01	2,996	461,423	39,740	Aug 05 05:18 PM
Cooke Julie	Chief Human Resources Officer	Jul 16 '24	Option Exercise	61.82	900	55,638	19,102	Jul 18 05:12 PM
Cooke Julie	Chief Human Resources Officer	Jul 16 '24	Sale	150.04	900	135,036	18,202	Jul 18 05:12 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 16 '24	Option Exercise	103.52	1,957	202,589	9,064	Jul 18 05:00 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 16 '24	Sale	150.03	2,857	428,627	6,607	Jul 18 05:00 PM
LYONS GARY A	Director	Jul 16 '24	Option Exercise	42.76	930	39,767	119,977	Jul 18 04:54 PM
LYONS GARY A	Director	Jul 16 '24	Sale	150.03	930	139,530	119,047	Jul 18 04:54 PM
ABERNETHY MATT	Chief Financial Officer	Jul 16 '24	Option Exercise	73.60	900	66,240	32,428	Jul 18 04:45 PM
ABERNETHY MATT	Chief Financial Officer	Jul 16 '24	Sale	150.04	900	135,037	31,528	Jul 18 04:45 PM
Lippoldt Darin	Chief Legal Officer	Jul 16 '24	Option Exercise	79.02	7,004	553,456	46,744	Jul 18 04:41 PM
Lippoldt Darin	Chief Legal Officer	Jul 16 '24	Sale	150.00	7,004	1,050,590	39,740	Jul 18 04:41 PM
Cooke Julie	Chief Human Resources Officer	Jul 01 '24	Option Exercise	61.82	10,000	618,200	28,202	Jul 02 09:36 PM
Cooke Julie	Chief Human Resources Officer	Jul 01 '24	Sale	140.19	10,000	1,401,864	18,202	Jul 02 09:36 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 01 '24	Option Exercise	79.02	272	21,493	7,779	Jul 02 09:09 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 01 '24	Sale	138.11	272	37,566	7,507	Jul 02 09:09 PM
Delaet Ingrid	Chief Regulatory Officer	May 31 '24	Option Exercise	79.02	273	21,572	7,780	Jun 04 04:23 PM
Delaet Ingrid	Chief Regulatory Officer	May 31 '24	Sale	136.55	273	37,278	7,507	Jun 04 04:23 PM
SHERWIN STEPHEN A	Director	May 29 '24	Option Exercise	44.68	40,000	1,787,350	51,504	May 30 04:38 PM
SHERWIN STEPHEN A	Director	May 29 '24	Sale	133.46	40,000	5,338,564	26,504	May 30 04:38 PM
Sharp Shalini	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 05:35 PM
Sharp Shalini	Director	May 17 '24	Sale	141.90	1,106	156,943	994	May 21 05:35 PM
POPS RICHARD F	Director	May 17 '24	Option Exercise	0.00	4,199	0	33,711	May 21 05:27 PM
POPS RICHARD F	Director	May 17 '24	Sale	141.84	2,100	297,860	31,611	May 21 05:27 PM
MORROW GEORGE J	Director	May 17 '24	Option Exercise	0.00	4,199	0	4,199	May 21 05:15 PM
Norwalk Leslie V	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 05:06 PM
Norwalk Leslie V	Director	May 17 '24	Sale	141.82	1,106	156,850	994	May 21 05:06 PM
LYONS GARY A	Director	May 17 '24	Option Exercise	0.00	2,100	0	119,047	May 21 04:57 PM
SHERWIN STEPHEN A	Director	May 17 '24	Option Exercise	0.00	4,199	0	26,504	May 21 04:51 PM
Mercier Johanna	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 04:46 PM
LYONS GARY A	Director	May 14 '24	Option Exercise	42.76	12,500	534,500	129,447	May 16 04:55 PM
LYONS GARY A	Director	May 14 '24	Sale	135.63	12,500	1,695,370	116,947	May 16 04:55 PM
ABERNETHY MATT	Chief Financial Officer	May 14 '24	Option Exercise	73.60	15,000	1,104,000	46,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 15 '24	Option Exercise	73.60	15,000	1,104,000	46,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 15 '24	Sale	140.24	15,000	2,103,609	31,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 14 '24	Sale	135.66	15,000	2,034,826	31,528	May 16 04:40 PM
Delaet Ingrid	Chief Regulatory Officer	May 06 '24	Option Exercise	79.02	273	21,572	7,780	May 08 04:26 PM
Delaet Ingrid	Chief Regulatory Officer	May 06 '24	Sale	140.55	273	38,370	7,507	May 08 04:26 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Option Exercise	81.21	19,818	1,609,431	53,365	Apr 17 05:19 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Sale	133.36	19,818	2,643,020	40,778	Apr 17 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Option Exercise	79.02	272	21,493	7,779	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Sale	137.30	272	37,346	7,507	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Option Exercise	103.52	5,000	517,600	12,507	Mar 25 06:02 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Sale	145.06	5,000	725,320	7,507	Mar 25 06:02 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Option Exercise	80.90	75,000	6,067,628	110,299	Mar 15 05:33 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Sale	139.38	75,000	10,453,417	40,778	Mar 15 05:33 PM
MORROW GEORGE J	Director	Mar 14 '24	Option Exercise	39.79	40,000	1,591,600	20,000	Mar 15 05:25 PM
MORROW GEORGE J	Director	Mar 14 '24	Sale	139.42	40,000	5,576,710	0	Mar 15 05:25 PM
POPS RICHARD F	Director	Mar 13 '24	Option Exercise	42.76	23,200	992,032	52,712	Mar 15 05:19 PM
POPS RICHARD F	Director	Mar 13 '24	Sale	140.33	23,200	3,255,621	29,512	Mar 15 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Option Exercise	106.02	3,000	318,060	10,507	Mar 15 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Sale	140.14	3,000	420,419	7,507	Mar 15 05:15 PM
POPS RICHARD F	Director	Mar 08 '24	Option Exercise	42.76	1,700	72,692	31,212	Mar 12 06:47 PM
POPS RICHARD F	Director	Mar 11 '24	Option Exercise	42.76	100	4,276	29,612	Mar 12 06:47 PM
POPS RICHARD F	Director	Mar 08 '24	Sale	140.05	1,700	238,078	29,512	Mar 12 06:47 PM
POPS RICHARD F	Director	Mar 11 '24	Sale	140.00	100	14,000	29,512	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Option Exercise	106.02	1,800	190,836	9,307	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Option Exercise	106.02	200	21,204	7,707	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Sale	140.03	1,800	252,053	7,507	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Sale	140.00	200	28,000	7,507	Mar 12 06:38 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Option Exercise	79.02	6,544	517,107	10,007	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Option Exercise	79.02	273	21,572	7,780	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Sale	135.34	6,544	885,638	7,507	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Sale	135.51	273	36,994	7,507	Feb 29 07:02 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Option Exercise	53.67	75,000	4,025,043	93,759	Feb 29 06:55 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Sale	134.69	75,000	10,101,608	40,616	Feb 29 06:55 PM
Norwalk Leslie V	Director	Feb 27 '24	Option Exercise	84.95	8,000	679,600	8,000	Feb 29 06:50 PM
Norwalk Leslie V	Director	Feb 27 '24	Sale	135.67	8,000	1,085,388	0	Feb 29 06:50 PM
POPS RICHARD F	Director	Feb 20 '24	Option Exercise	12.98	15,000	194,700	44,512	Feb 22 05:11 PM
POPS RICHARD F	Director	Feb 20 '24	Sale	132.47	15,000	1,987,047	29,512	Feb 22 05:11 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '24	Sale	132.96	1,114	148,122	23,716	Feb 15 05:51 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '24	Sale	132.94	1,432	190,371	13,128	Feb 15 05:48 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '24	Sale	132.99	1,098	146,028	39,740	Feb 15 05:45 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Sale	133.02	2,832	376,700	514,596	Feb 15 05:43 PM
Gano Kyle	Chief Business Development Off	Feb 13 '24	Sale	132.89	1,352	179,674	135,166	Feb 15 05:40 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '24	Sale	133.03	716	95,253	7,507	Feb 15 05:38 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '24	Sale	133.04	796	105,902	17,976	Feb 15 05:35 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '24	Sale	133.07	1,811	240,996	4,895	Feb 15 05:33 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '24	Sale	133.01	1,098	146,050	40,616	Feb 15 05:29 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '24	Sale	132.85	1,352	179,612	31,528	Feb 15 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Neurocrine Biosciences, Inc

Upgrade your FINVIZ experience